118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)

I. Melero,M.J. De Miguel,G. Alonso Casal,G.A. De Velasco Oria, E. Ramelyte, M. Joerger, J. Martin-Liberal, D. König, C.M. Sayehli, T. Gromke, M.E. RodrÍguez-Ruiz, E. Calvo, E. Garralda, J.J. Soto-Castillo, R. Dummer, J. Esteban Villarrubia,M-E. Goebeler, P. Fettes, K. Klar, E. Leo

Immuno-Oncology and Technology（2023）

引用 0|浏览1

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要